Profile data is unavailable for this security.
About the company
Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence and is advancing senolytic programs primarily in ophthalmologic disorders. In addition, it has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1967 is its back-up compound to UBX1325. UBX2089, an α-Klotho hormone drug candidate, which is being researched for multiple neurology indications.
- Revenue in USD (TTM)0.00
- Net income in USD-34.78m
- Incorporated2009
- Employees19.00
- LocationUNITY Biotechnology Inc285 EAST GRAND AVENUESOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (650) 416-1192
- Fax+1 (302) 655-5049
- Websitehttps://unitybiotechnology.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAB Biotherapeutics Inc | 2.60m | -39.87m | 24.37m | 57.00 | -- | 0.4613 | -- | 9.36 | -6.26 | -6.26 | 0.396 | 5.72 | 0.0456 | -- | 5.44 | 45,657.37 | -69.91 | -- | -86.60 | -- | -- | -- | -1,531.84 | -- | -- | -- | 0.0762 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| Lisata Therapeutics Inc | 0.00 | -20.05m | 24.42m | 25.00 | -- | 0.568 | -- | -- | -2.46 | -2.46 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -35.01 | -45.97 | -38.40 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Iterum Therapeutics PLC | 0.00 | -35.58m | 24.83m | 14.00 | -- | -- | -- | -- | -2.64 | -2.64 | 0.00 | -0.3734 | 0.00 | -- | -- | 0.00 | -91.54 | -118.12 | -136.45 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 1.44 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| TherapeuticsMD Inc | 1.20m | -6.20m | 25.60m | 1.00 | -- | 0.8931 | -- | 21.35 | -0.58 | -0.6955 | 0.1103 | 2.49 | 0.0236 | -- | 0.4556 | 1,199,000.00 | -12.19 | -53.35 | -16.34 | -111.61 | 73.89 | 86.67 | -516.93 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Medicine Man Technologies Inc | 172.45m | -42.70m | 25.61m | 729.00 | -- | 0.2821 | -- | 0.1485 | -1.60 | -1.60 | 3.01 | 1.61 | 0.5064 | 3.99 | 39.49 | 236,553.90 | -10.15 | -8.33 | -11.95 | -9.85 | 44.08 | 45.57 | -20.03 | -15.71 | 0.5027 | 0.3143 | 0.5679 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
| Acasti Pharma Inc | 0.00 | -38.77m | 25.65m | 32.00 | -- | 0.3966 | -- | -- | -5.06 | -5.06 | 0.00 | 6.88 | 0.00 | -- | -- | -- | -40.18 | -45.71 | -41.30 | -50.84 | -- | -- | -- | -69,798.47 | -- | -14.38 | 0.00 | -- | -- | -- | -332.11 | -- | -45.53 | -- |
| Aprea Therapeutics Inc | 963.81k | -12.72m | 25.90m | 7.00 | -- | 0.8955 | -- | 26.87 | -3.32 | -3.32 | 0.2503 | 5.57 | 0.0296 | -- | -- | 137,687.10 | -39.00 | -68.66 | -43.83 | -77.19 | -- | -- | -1,319.45 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| Unity Biotechnology Inc | 0.00 | -34.78m | 26.02m | 19.00 | -- | 1.08 | -- | -- | -2.33 | -2.33 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -40.18 | -47.21 | -48.47 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Singular Genomics Systems Inc | 2.49m | -96.21m | 27.02m | 255.00 | -- | 0.1724 | -- | 10.85 | -1.31 | -1.31 | 0.034 | 2.12 | 0.0091 | 0.233 | 32.98 | 9,764.71 | -35.33 | -- | -37.29 | -- | -41.49 | -- | -3,863.90 | -- | 9.54 | -- | 0.0614 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -2.88m | 27.17m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 27.25m | 3.00 | -- | 1.04 | -- | 63.16 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| Oncternal Therapeutics Inc | 1.15m | -36.38m | 27.26m | 27.00 | -- | 1.19 | -- | 23.68 | -12.35 | -12.35 | 0.3907 | 7.75 | 0.0263 | -- | -- | 42,629.63 | -83.23 | -49.40 | -95.97 | -54.51 | -- | -- | -3,160.73 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -47.99m | 27.49m | 40.00 | -- | 4.88 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2821 | 0.00 | -- | -- | 0.00 | -75.51 | -86.35 | -112.64 | -106.38 | -- | -- | -- | -11,853.94 | -- | -84.18 | 0.6277 | -- | -- | -- | -3.78 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -8.05m | 27.78m | 8.00 | -- | 11.07 | -- | -- | -0.7249 | -0.7249 | 0.00 | 0.1048 | 0.00 | -- | -- | 0.00 | -172.23 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| BioVie Inc | 0.00 | -37.18m | 27.79m | 18.00 | -- | 1.47 | -- | -- | -0.9626 | -0.9626 | 0.00 | 0.3104 | 0.00 | -- | -- | 0.00 | -94.32 | -456.35 | -149.75 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.2969 | -- | -- | -- | -92.67 | -- | -- | -- |
Data as of Jun 04 2024. Currency figures normalised to UNITY Biotechnology Inc's reporting currency: US Dollar USD
12.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Alyeska Investment Group LPas of 31 Mar 2024 | 920.01k | 5.48% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 557.35k | 3.32% |
| Geode Capital Management LLCas of 31 Mar 2024 | 134.13k | 0.80% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 109.79k | 0.65% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 106.94k | 0.64% |
| Citadel Securities LLCas of 31 Mar 2024 | 93.59k | 0.56% |
| UBS O'Connor LLCas of 31 Mar 2024 | 70.40k | 0.42% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 50.00k | 0.30% |
| Wells Fargo Advisors Financial Network LLCas of 31 Mar 2024 | 43.37k | 0.26% |
| Cercano Management LLCas of 31 Mar 2024 | 41.24k | 0.25% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
